Novo Nordisk has launched a direct-to-consumer (DTC) option for uninsured or under-insured people wanting to access its GLP-1 agonist weight-loss drug Wegovy, cutting the drug's price in half to $499 per month for those paying out-of-pocket.

诺和诺德为无保险或保险不足的人群推出了直接面向消费者的（DTC）选项，以获取其GLP-1激动剂减肥药物Wegovy，将自费支付的药物价格减半至每月499美元。

The launch of the NovoCare Pharmacy service follows the removal of semaglutide – the active ingredient in

诺和关怀药房服务的推出是在司美格鲁肽（semaglutide）这种活性成分被移除之后进行的。

Wegovy

韦哥维

– from the FDA's shortage list and comes a few months after rival Eli Lilly adopted a similar DTC strategy with its LillyDirect service for Zepbound (tirzepatide).

– 来自FDA的短缺名单，几个月前，其竞争对手礼来公司也为其Zepbound（替尔泊肽）采用了类似的直接面向消费者的策略，推出了LillyDirect服务。

NovoCare offers home delivery of all doses of Wegovy – 0.25mg, 0.5mg, 1.0mg, 1.7mg and 2.4mg autoinjectors – to people who are uninsured or those with commercial insurance that does not cover weight loss medications, although the company notes that 90% of patients taking the drug are insured with a co-pay of between $0 and $25 per month..

NovoCare 为没有保险或拥有不涵盖减肥药物的商业保险的人群提供所有剂量的 Wegovy（0.25毫克、0.5毫克、1.0毫克、1.7毫克和2.4毫克自动注射器）送货上门服务，尽管该公司指出，90% 的用药患者拥有保险，每月自付费用在 0 至 25 美元之间。

Novo Nordisk also said that it would be updating the price of the drug 'so that cash-paying patients who use traditional retail pharmacies will also benefit from this lower price,' and confirmed that all dose strengths of Wegovy now meet or exceed 'current and projected US demand.'

诺和诺德还表示，将更新药品价格，“以便在传统零售药店使用现金支付的患者也能从这一较低价格中受益”，并确认所有剂量强度的Wegovy现在都“达到或超过当前和预计的美国需求”。

Lilly recently

莉莉最近

extended

扩展的

the range of Zepbound products available through LillyDirect with the addition of high-dose vials at $499 and reduced the price of the lowest-dose 2.5mg vial – the starting dose – to $349 per month. At the moment, only the vial formulations are available through LillyDirect, so Novo Nordisk may have claimed a competitive edge by making its autoinjector range available DTC..

通过LillyDirect提供的Zepbound产品系列增加了高剂量瓶装，售价为499美元，并将最低剂量2.5mg瓶装（起始剂量）的价格降至每月349美元。目前，只有瓶装制剂通过LillyDirect供应，因此诺和诺德可能通过将其自动注射器系列直接面向消费者提供而获得竞争优势。

Both Novo Nordisk and Lilly are responding to the competition to their

诺和诺德和礼来都对竞争做出了回应，

obesity

肥胖症

products from compounding pharmacies, which have been able to offer discounted versions of semaglutide and tirzepatide under FDA regulations applying to medicines deemed to be in short supply.

复合药店的产品，根据美国食品药品监督管理局（FDA）关于供应短缺药物的规定，这些药店能够提供司美鲁肽和替西帕肽的折扣版本。

With both drugs now officially off the shortage list, the clock has started ticking towards the end of that dispensation. Although compounders are suing the FDA in an attempt to reverse its decisions.

随着这两种药物现在正式脱离短缺名单，这一分配的倒计时已经开始。尽管复合药剂师正在起诉FDA，试图推翻其决定。

For tirzepatide, the legal right to compound came to an end on 18th February for state-licensed pharmacy or physician compounders, while outsourcing facilities will have to stop by 19th March. For semaglutide, the corresponding dates are 22nd April and 22nd May, respectively.

对于替尔泊肽，州立许可药房或医生配制者的合法配制权已于 2 月 18 日结束，而外包机构则必须在 3 月 19 日前停止。对于司美格鲁肽，相应的日期分别为 4 月 22 日和 5 月 22 日。

Meanwhile, both companies have warned about the risks associated with sourcing the drugs from other sources, particularly rogue online pharmacies that may supply counterfeit versions with no active ingredient, the wrong active ingredient, and/or harmful contaminants.

同时，两家公司都警告了从其他渠道采购这些药物的风险，特别是那些可能提供没有活性成分、活性成分错误和/或有害污染物的假药的非法网上药店。

In a statement, Novo Nordisk said that 'amidst the dangers of fake or illegitimate compounded 'semaglutide', NovoCare Pharmacy offers reliable access to authentic, FDA-approved Wegovy in our once-weekly, single-dose pen.'

诺和诺德在一份声明中表示：“在假货或非法复方‘司美格鲁肽’的危险之中，诺和关怀药房提供可靠途径获取正宗、FDA批准的每周一次单剂量笔型Wegovy。”